Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NTB-928 in Relapsed/Refractory Ovarian Carcinoma
NCT07690189Phase 1Recruiting
- Sponsor
- TeneoSeven
- Start
- Jun 2026
- Primary completion
- Jun 2028
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of TNB-928B in ovarian carcinoma, sponsored by TeneoSeven. Primary endpoints: Dose-limiting toxicities at 35 days, Adverse events and serious adverse events at 3 years and 11 more. Started Jun 2026; status: recruiting.
02
Drugs
TNB-928B
03
Conditions
ovarian carcinoma
Beyond the preview
Go deeper on NCT07690189.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07690189.